Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.39 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.39 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.39 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531454 | 0.89 | TAAR1 (0.41) | TAAR1HPGDALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL4512033 | 0.81 | TAAR1 (0.43) | TAAR1AOC3HPGDALDH1A1CYP1A2 | |
| SCHEMBL18567626 | 0.80 | TAAR1 (0.50) | TAAR1AOC3ALDH1A1LMNAHTR3E | |
| SCHEMBL4727500 | 0.80 | KMT2A (0.53) | ALDH1A1CYP1A2LMNACCR6NPC1 | |
| SCHEMBL18568293 | 0.79 | TAAR1 (0.53) | TAAR1AOC3HIF1AHTR3EHTR3B | |
| SCHEMBL10882173 | 0.75 | TAAR1 (0.47) | TAAR1AOC3HTR3EHTR3BHTR3A | |
| SCHEMBL4529675 | 0.74 | TAAR1 (0.49) | TAAR1AOC3HPGDALDH1A1HTR3E | |
| SCHEMBL18422574 | 0.73 | TAAR1 (0.62) | TAAR1AOC3ALDH1A1HIF1AHTR3E | |
| SCHEMBL4517362 | 0.73 | TAAR1 (0.40) | TAAR1AOC3HPGDALDH1A1CYP1A2 | |
| SCHEMBL1180759 | 0.72 | TAAR1 (0.39) | TAAR1AOC3HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2323656-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2315589-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| WO-2010019098-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009154555-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| EP-2132189-A1 | SALTS OF A SELECTIVE BETA-2 ANDRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| EP-2124941-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | Argenta Discovery Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009139708-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2008104790-A1 | SALTS OF A SELECTIVE BETA-2 ANDRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ADRB2, ADRB1, ADRA2C | TAAR1 70/4885AOC3 900/4885HPGD 1116/4885 |
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ADRB2, ADRA2A, ADRA2B | TAAR1 75/4885AOC3 1861/4885HPGD 1715/4885 |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TAAR1 205/4885AOC3 1046/4885HPGD 1542/4885 |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TAAR1 206/4885AOC3 822/4885HPGD 1519/4885 |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TAAR1 187/4885AOC3 920/4885HPGD 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.